TY - JOUR

T1 - Role of procalcitonin in diagnosis and prognosis of pneumonia caused by the new coronavirus infection 2019 (COVID-19)

AU - Kovaleva, Anna Ya

AU - Nikolaev, Konstantin Yu

AU - Agamian, Ekaterina R.

AU - Lifshits, Galina I.

N1 - Публикация для корректировки.

PY - 2023

Y1 - 2023

N2 - The aim of the research. To determine the role of procalcitonin in the diagnosis and prognosis of patients with pneumonia against the background of the new coronavirus infection. Material and methods. The study included 41 patients with community-acquired pneumonia and confirmed new coronavirus infection COVID-19. All patients underwent clinical and instrumental examination, as well as procalcitonin level analysis using the “BioTest Procalcitonin Test PCT” testing system. Results. High procalcitonin levels of ≥0.5 ng/ml were determined in 20% of patients with COVID-associated community-acquired pneumonia. A high level of procalcitonin was directly associated with a number of clinical, laboratory and instrumental parameters: hydrothorax (χ2=6.964, p=0.008), extensive lung damage (>60%) CT results (r=0.371, p=0.017), neutrophilia ≥5.5x109/l (r=0.344, p=0.028), creatinine (r=0.320, p=0.042), CPK (r=0.478, p=0.002). According to the results of multivariate regression analysis, it has been determined that a high value of procalcitonin increases the risk of extensive lung damage (≥60% on CT) by 4 times (p=0.023), the risk of increased creatinine (≥119 µmol/l) - by 3 times (p=0.041) and an increase in the duration of hospitalisation (≥24 days) by 5 times (p=0.046). Conclusion. The data confirm the need to determine the level of procalcitonin in the blood at the time of hospitalisation in patients with COVID-associated pneumonia in order to prescribe a more effective treatment. A semi-quantitative rapid test makes it possible to do it quickly at a minimal cost.

AB - The aim of the research. To determine the role of procalcitonin in the diagnosis and prognosis of patients with pneumonia against the background of the new coronavirus infection. Material and methods. The study included 41 patients with community-acquired pneumonia and confirmed new coronavirus infection COVID-19. All patients underwent clinical and instrumental examination, as well as procalcitonin level analysis using the “BioTest Procalcitonin Test PCT” testing system. Results. High procalcitonin levels of ≥0.5 ng/ml were determined in 20% of patients with COVID-associated community-acquired pneumonia. A high level of procalcitonin was directly associated with a number of clinical, laboratory and instrumental parameters: hydrothorax (χ2=6.964, p=0.008), extensive lung damage (>60%) CT results (r=0.371, p=0.017), neutrophilia ≥5.5x109/l (r=0.344, p=0.028), creatinine (r=0.320, p=0.042), CPK (r=0.478, p=0.002). According to the results of multivariate regression analysis, it has been determined that a high value of procalcitonin increases the risk of extensive lung damage (≥60% on CT) by 4 times (p=0.023), the risk of increased creatinine (≥119 µmol/l) - by 3 times (p=0.041) and an increase in the duration of hospitalisation (≥24 days) by 5 times (p=0.046). Conclusion. The data confirm the need to determine the level of procalcitonin in the blood at the time of hospitalisation in patients with COVID-associated pneumonia in order to prescribe a more effective treatment. A semi-quantitative rapid test makes it possible to do it quickly at a minimal cost.

KW - bacterial infection

KW - coronavirus infection

KW - pneumonia

KW - procalcitonin

UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85179415198&origin=inward&txGid=a204b7c6f4f62903d5694e571c8c184f

UR - https://www.mendeley.com/catalogue/ff4a0d61-e7ba-373f-a1f7-67240939cfb1/

U2 - 10.20333/25000136-2023-5-74-80

DO - 10.20333/25000136-2023-5-74-80

M3 - Article

VL - 2023

SP - 74

EP - 80

JO - Сибирское медицинское обозрение

JF - Сибирское медицинское обозрение

SN - 1819-9496

ER -